Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery

Sarah K. Gross, Bo Sung Shim, Raymond T. Bartus, Dan Deaver, Zachary McEachin, Alexandre Bétourné, Nicholas M. Boulis, Nicholas J. Maragakis

Research output: Contribution to journalArticle

Abstract

Neurotrophic factors as candidates for ALS therapeutics have previously been studied in the context of attempts to slow disease progression. For a variety of reasons, clinical trials of neurotrophic factors have failed to show efficacy in ALS patients. Previous studies in Parkinson's Disease (PD) models have shown promise with the use of recombinant adeno-associated virus serotype-2 (rAAV2)-neurturin (NRTN) [AAV2-NRTN] providing neuroprotection and behavioral improvements in preclinical models which subsequently resulted in several clinical studies in patients with PD. Given that this neurotrophic compound has not been studied in the context of ALS, we conducted a study of AAV2-NRTN to assess the preclinical safety, tolerability, biodistribution, and efficacy of this compound in an ALS mouse model. SOD1G93A mice were injected with AAV2-NRTN intraspinally at several doses into the cervical spinal cord at 60 days of age. NRTN expression was noted in motor neurons (MNs) of the targeted cervical spinal cord as well as in their neuromuscular junction projections but not in the lumbar spinal cord, which was not targeted. Neuropathologically, a dose-dependent neuroprotective effect was seen in cervical MNs and neuromuscular junctions that was reflected in a slowing of forelimb grip strength decline. As expected, this neuroprotection was found to be focal and was not seen beyond the immediate region of injection. Overall, there were no increases in morbidity, changes in serum chemistries or blood counts and no cases of drug-related mortality. Because there is a broad clinical experience for this compound, these data provide evidence to support further investigation of AAV2-NRTN as a potential ALS therapeutic.

Original languageEnglish (US)
Article number113091
JournalExperimental Neurology
Volume323
DOIs
StatePublished - Jan 2020

Fingerprint

Neurturin
Dependovirus
Neuromuscular Junction
Nerve Growth Factors
Motor Neurons
Parkinson Disease
Spinal Cord
Forelimb
Hand Strength
Neuroprotective Agents
Disease Progression
Neuroprotection
Clinical Trials
Morbidity
Safety
Injections
Mortality
Serogroup
Therapeutics
Serum

Keywords

  • Amyotrophic lateral sclerosis
  • Gene therapy
  • Neurodegeneration
  • Neuroprotection
  • Viral vector

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. / Gross, Sarah K.; Shim, Bo Sung; Bartus, Raymond T.; Deaver, Dan; McEachin, Zachary; Bétourné, Alexandre; Boulis, Nicholas M.; Maragakis, Nicholas J.

In: Experimental Neurology, Vol. 323, 113091, 01.2020.

Research output: Contribution to journalArticle

Gross, Sarah K. ; Shim, Bo Sung ; Bartus, Raymond T. ; Deaver, Dan ; McEachin, Zachary ; Bétourné, Alexandre ; Boulis, Nicholas M. ; Maragakis, Nicholas J. / Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery. In: Experimental Neurology. 2020 ; Vol. 323.
@article{4495be3878cc4d8e898d4e751c82d472,
title = "Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery",
abstract = "Neurotrophic factors as candidates for ALS therapeutics have previously been studied in the context of attempts to slow disease progression. For a variety of reasons, clinical trials of neurotrophic factors have failed to show efficacy in ALS patients. Previous studies in Parkinson's Disease (PD) models have shown promise with the use of recombinant adeno-associated virus serotype-2 (rAAV2)-neurturin (NRTN) [AAV2-NRTN] providing neuroprotection and behavioral improvements in preclinical models which subsequently resulted in several clinical studies in patients with PD. Given that this neurotrophic compound has not been studied in the context of ALS, we conducted a study of AAV2-NRTN to assess the preclinical safety, tolerability, biodistribution, and efficacy of this compound in an ALS mouse model. SOD1G93A mice were injected with AAV2-NRTN intraspinally at several doses into the cervical spinal cord at 60 days of age. NRTN expression was noted in motor neurons (MNs) of the targeted cervical spinal cord as well as in their neuromuscular junction projections but not in the lumbar spinal cord, which was not targeted. Neuropathologically, a dose-dependent neuroprotective effect was seen in cervical MNs and neuromuscular junctions that was reflected in a slowing of forelimb grip strength decline. As expected, this neuroprotection was found to be focal and was not seen beyond the immediate region of injection. Overall, there were no increases in morbidity, changes in serum chemistries or blood counts and no cases of drug-related mortality. Because there is a broad clinical experience for this compound, these data provide evidence to support further investigation of AAV2-NRTN as a potential ALS therapeutic.",
keywords = "Amyotrophic lateral sclerosis, Gene therapy, Neurodegeneration, Neuroprotection, Viral vector",
author = "Gross, {Sarah K.} and Shim, {Bo Sung} and Bartus, {Raymond T.} and Dan Deaver and Zachary McEachin and Alexandre B{\'e}tourn{\'e} and Boulis, {Nicholas M.} and Maragakis, {Nicholas J.}",
year = "2020",
month = "1",
doi = "10.1016/j.expneurol.2019.113091",
language = "English (US)",
volume = "323",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Focal and dose-dependent neuroprotection in ALS mice following AAV2-neurturin delivery

AU - Gross, Sarah K.

AU - Shim, Bo Sung

AU - Bartus, Raymond T.

AU - Deaver, Dan

AU - McEachin, Zachary

AU - Bétourné, Alexandre

AU - Boulis, Nicholas M.

AU - Maragakis, Nicholas J.

PY - 2020/1

Y1 - 2020/1

N2 - Neurotrophic factors as candidates for ALS therapeutics have previously been studied in the context of attempts to slow disease progression. For a variety of reasons, clinical trials of neurotrophic factors have failed to show efficacy in ALS patients. Previous studies in Parkinson's Disease (PD) models have shown promise with the use of recombinant adeno-associated virus serotype-2 (rAAV2)-neurturin (NRTN) [AAV2-NRTN] providing neuroprotection and behavioral improvements in preclinical models which subsequently resulted in several clinical studies in patients with PD. Given that this neurotrophic compound has not been studied in the context of ALS, we conducted a study of AAV2-NRTN to assess the preclinical safety, tolerability, biodistribution, and efficacy of this compound in an ALS mouse model. SOD1G93A mice were injected with AAV2-NRTN intraspinally at several doses into the cervical spinal cord at 60 days of age. NRTN expression was noted in motor neurons (MNs) of the targeted cervical spinal cord as well as in their neuromuscular junction projections but not in the lumbar spinal cord, which was not targeted. Neuropathologically, a dose-dependent neuroprotective effect was seen in cervical MNs and neuromuscular junctions that was reflected in a slowing of forelimb grip strength decline. As expected, this neuroprotection was found to be focal and was not seen beyond the immediate region of injection. Overall, there were no increases in morbidity, changes in serum chemistries or blood counts and no cases of drug-related mortality. Because there is a broad clinical experience for this compound, these data provide evidence to support further investigation of AAV2-NRTN as a potential ALS therapeutic.

AB - Neurotrophic factors as candidates for ALS therapeutics have previously been studied in the context of attempts to slow disease progression. For a variety of reasons, clinical trials of neurotrophic factors have failed to show efficacy in ALS patients. Previous studies in Parkinson's Disease (PD) models have shown promise with the use of recombinant adeno-associated virus serotype-2 (rAAV2)-neurturin (NRTN) [AAV2-NRTN] providing neuroprotection and behavioral improvements in preclinical models which subsequently resulted in several clinical studies in patients with PD. Given that this neurotrophic compound has not been studied in the context of ALS, we conducted a study of AAV2-NRTN to assess the preclinical safety, tolerability, biodistribution, and efficacy of this compound in an ALS mouse model. SOD1G93A mice were injected with AAV2-NRTN intraspinally at several doses into the cervical spinal cord at 60 days of age. NRTN expression was noted in motor neurons (MNs) of the targeted cervical spinal cord as well as in their neuromuscular junction projections but not in the lumbar spinal cord, which was not targeted. Neuropathologically, a dose-dependent neuroprotective effect was seen in cervical MNs and neuromuscular junctions that was reflected in a slowing of forelimb grip strength decline. As expected, this neuroprotection was found to be focal and was not seen beyond the immediate region of injection. Overall, there were no increases in morbidity, changes in serum chemistries or blood counts and no cases of drug-related mortality. Because there is a broad clinical experience for this compound, these data provide evidence to support further investigation of AAV2-NRTN as a potential ALS therapeutic.

KW - Amyotrophic lateral sclerosis

KW - Gene therapy

KW - Neurodegeneration

KW - Neuroprotection

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=85074687813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074687813&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2019.113091

DO - 10.1016/j.expneurol.2019.113091

M3 - Article

C2 - 31678350

AN - SCOPUS:85074687813

VL - 323

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

M1 - 113091

ER -